A new heart failure drug class, the angiotensin receptor-neprilysin inhibitors, involves the inhibition of neprilysin, which is an Αβ degrading enzyme and thus may increase Aβ1-40 plasma levels (Table 3). This evidence concerns the gene MME and heart failure.